After taking a pill, the drugs it contains are distributed throughout the human body, reaching the tissues and cells affected by diseases and performing their intended function. However, they also enter healthy cells, where they often cause more harm than good. In a study published in the journal “Nature Communications”, a multidisciplinary team led by PROXIDRUGS project lead Felix Hausch and Alexander Loewer from TU Darmstadt has now shown how proteins occurring naturally in human cells can...

Recent changes at Genentech have brought a wider debate into sharp focus. As the company makes AI increasingly central to its research strategy, several internationally renowned scientists have been let go as part of a broader restructuring and shift in priorities. In a new Comment in Nature Cell Biology, PROXIDRUGS Speaker Ivan Đikić from Goethe University Frankfurt and Henning Walczak from UCL Cancer Institute and University of Cologne ask what such changes could mean for the future of...

A recent report by 17:30 Live Rheinland-Pfalz/Hessen featured a new approach from cancer research in Frankfurt: Prof. Volker Dötsch, PROXIDRUGS researcher, and Dr. Andreas Joerger are working to stabilize mutated variants of the tumor suppressor protein p53. p53 is often referred to as the “guardian of the genome” because it can detect damaged cells and activate important protective mechanisms. In many tumors, however, p53 is mutated and loses its function. One central problem is that many of...